Back
Ares Commercial Real Estate Vs. Sarepta Therapeutics Industry Stock Comparison
Buy
62
ACRE
Ares Commercial Real Estate
Last Price:
7.23
Seasonality Move:
0.17%
Sell
49
SRPT
Sarepta Therapeutics
Last Price:
130.47
Seasonality Move:
14.88%
Buy
62
Ares Commercial Real Estate (ACRE)
is a Buy
Is Ares Commercial Real Estate a Buy, Sell or Hold?
- The current Ares Commercial Real Estate [ACRE] share price is $7.22. The Score for ACRE is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.
- ACRE is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
49
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
ACRE Stock Price Chart
What is Ares Commercial Real Estate's stock price today?
-
The Ares Commercial Real Estate share price today is $7.22
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ACRE is experiencing slight buying pressure.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $130.50
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
ACRE Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.13 | Buy |
| Relative Strength Index (14 RSI): | 60.38 | Buy |
| Chaikin Money Flow: | 27243 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (6.46 - 7.16) | Buy |
| Bollinger Bands (100): | (6.63 - 7.43) | Buy |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -2.3 | Sell |
| Relative Strength Index (14 RSI): | 64.59 | Buy |
| Chaikin Money Flow: | 3149400 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (111.02 - 128.88) | Buy |
| Bollinger Bands (100): | (119.18 - 142.3) | Sell |
ACRE Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 7.11 | Buy |
| 20-day SMA: | 6.89 | Buy |
| 50-day SMA: | 6.88 | Buy |
| 200-day SMA: | 7.1 | Buy |
| 8-day EMA: | 7.14 | Buy |
| 20-day EMA: | 6.98 | Buy |
| 50-day EMA: | 6.91 | Buy |
| 200-day EMA: | 7.43 | Sell |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 112.07 | Buy |
| 20-day SMA: | 117.27 | Buy |
| 50-day SMA: | 121.92 | Buy |
| 200-day SMA: | 129.99 | Buy |
| 8-day EMA: | 116.28 | Buy |
| 20-day EMA: | 117.14 | Buy |
| 50-day EMA: | 121.91 | Buy |
| 200-day EMA: | 125.98 | Buy |
Ares Commercial Real Estate Earnings Growth & ACRE Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.06 per share, a decrease next quarter of $0.00 per share, a decrease this year of $1.06 per share, and an increase next year of $1.00 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.87 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $8.76 per share.
Ares Commercial Real Estate Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||